TVGN - יחס חוב להיוון בספרים Tevogen Bio Holdings Inc.

Tevogen Bio Holdings (TVGN) minimizes medical risks by developing methods to enhance immune defense for combating cancer and viruses. Successful trial phases of T-cell products and potential licensing deals are driving business growth. A unique software for developing non-rejection therapies and strong patent protection provide a technological advantage. The current indicator is 0.00, and the asset's market dynamics on GURU.Markets are available below.

To identify a fundamental support level for Tevogen Bio Holdings (TVGN) equity, it is essential to correlate the value of the ExCITE platform patents with the debt load under strict FDA oversight. By analyzing the company's debt-to-book capitalization ratio on GURU.Markets, an investor can determine the ratio of total liabilities to book value, enabling an assessment of default risk and the asset's financial stability in the face of regulatory challenges.